About the company: Merxin is a designer, developer and supplier of generic and customised drug delivery and medical device platforms
Interviewee name: Phillipe Rogueda
Job title: Chief Business Officer
- Who is Merxin? What products/solutions are you offering?
We are designers and suppliers of inhaler devices that treat lung diseases, reduce vaping risks, and make cannabis therapies reliable. Our DNA is in the pharma industry: we deliver quality, reliability and efficacy. Our devices include a multidose dry powder inhalers, capsule dry powder inhaler, soft mist inhalers, no heat no PG vaping devices and devices tailored to cannabinoid delivery to the lungs and nasal cavities. Our customers take our devices and combine them with their drug formulation to make final dosage forms that are supplied to users and patients. We are based in King’s Lynn (Norfolk, UK).
We make the world healthier one breath at a time.
- What kind of trends are impacting your business at the moment? How can you help to tackle the challenges that the industry is facing?
The biggest challenge in the industry is the lack of end-to-end expertise in inhaler development: a company that not only understands mechanical and industrial design, but is able to work with partners to accelerate their product development.
We are not a cost centre, we create value for our partners.
Providing device platforms for customers is much more than creating drawings and making parts. Device design and development encompasses a wealth of engineering activity. Setting up supply chains requires extensive technical and business management activity. Providing product for clinical or commercial use means having appropriate quality systems and controls in place.
We take problems away from our customers. We do it so they don’t have to. We are a trusted partner. We are part of the solution. We support them with the device design and manufacturing and much more to speed up their product filing.
- What are your target markets and how do you plan to scale up for the global market?
Merxin is active in the fields of pharmaceuticals, cannabinoids therapies (inhaled cannabinoid therapies iCTx) and reduced risk nicotine inhalers (RiNih).
Our business is global and has been from the beginning. We provide unparalleled expertise and quality that is much sought after. We believe in quality and delivery reliability.
Our pharma market is the most global of the 3 markets we operate in. The cannabis applications are growing in importance at the speed of legislation change. We are part of this change, of making cannabinoid part of the standard pharmacopeia again. Changes at the WHO on their opinion of the use of cannabinoid as medicines is driving this change. It will soon become a global market. Reduced risk nicotine products are tremendously exciting to work on and growing in importance. We are on a mission to make vaping safe.
- How was Pharmapack 2019 for you?
Pharmapack was a great opportunity to meet many of our suppliers and save time. We are clearly at the beginning of a change at Pharmapack, where inhalation device and technology is making an entrance. We were glad to be part of that beginning.
Pharmapack was one of the better shows we have attended: well organised, well provided for, with enough time to meet people and be seen.
- Why did you choose to exhibit with us in 2019?
Many of our suppliers are present at Pharmapack, we wanted to meet them. We wanted them to see us and count us in. We are part of the supply chain. Pharmapack also enabled us to put on name on the map: inhalation drug delivery is main stream, we are making it so. Being seen at Pharmapack enables us to make inhaled drug delivery more accessible and offer new product options to companies who may not be familiar with his field.
- What are your general objectives when it comes to exhibiting and how does Pharmapack fit in?
Networking with current clients and finding new clients. Also spreading the Merxin brand to establish potentially unthought and new business relationships are our key goals at exhibitions.